

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 9/127	A1	(11) International Publication Number: WO 98/17256 (43) International Publication Date: 30 April 1998 (30.04.98)
(21) International Application Number: PCT/US97/18929 (22) International Filing Date: 21 October 1997 (21.10.97) (30) Priority Data: 60/028,931 22 October 1996 (22.10.96) US (71)(72) Applicant and Inventor: KIRPOTIN, Dmitri [RU/US]; 435 43rd Avenue #103, San Francisco, CA 94121 (US). (74) Agent: JOHNSON, Kristine, H.; Macheledt Bales & Johnson LLP, The Opera Galleria, Suite 219, 123 North College Avenue, Fort Collins, CO 80524 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: COMPOUND-LOADED LIPOSOMES AND METHODS FOR THEIR PREPARATION (57) Abstract A liposome composition containing encapsulated compound in stable precipitated form, and a method for producing the composition, are disclosed. The concentration of precipitated compound within the liposomes is several fold higher than that in the bulk medium, and the concentration of compound within the liposomes is not reduced in the presence of a proton or alkali metal-ion ionophore added to the suspension.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Compound-Loaded Liposomes and Methods for
Their Preparation**

This application claims benefit of U.S. Provisional Patent
Application Number 60/028,931, filed on October 22, 1996.

Field of the Invention

The present invention relates to liposomes loaded with compounds in
precipitated form, and to methods of producing such liposomes.

References

- Bally, M., *et al.*, *Biochim. Biophys. Acta* 812:66-76 (1985).
Barenholz, C., and Haran, G., *Chem. Abstr.* 114: 12199g (1988).
Carmichael, *et al.*, *Cancer Res.* 47:936-942 (1987).
Gabizon, A., *et al.*, *J. Liposome Res.* 1:123-135 (1988-89).
Haran, G., *et al.*, *Biochim. Biophys. Acta* 1151:201-215 (1993).
Lasic, D.D., *et al.*, *Biochim. Biophys. Acta* 1239: 145-156 (1995).
Lasic, DD, *Liposomes: From Physics to Applications* 315-317 (1993)
Maier, *et al.*, *Chem. Phys. Lipids* 40:333-345 (1986).
Mayer, *et al.*, *Biochim. Biophys. Acta* 816:294-302 (1985).
Mayer, *et al.*, *Biochim. Biophys. Acta* 857:123-126 (1986).
Nichols and Deamer, D., *Biochim. Biophys. Acta* 455:269-171 (1976).
Schwendener, *Cancer Drug Delivery* 3:123-129 (1986).
Schwendener, *et al.*, *Onkologie* 10:232-239 (1987).
Straubinger, R.M., *et al.*, *Biochemistry* 29:4929-4939 (1990).
Szoka, F.C., Jr., and Papahadjopoulos, D., *Proc. Natl. Acad. Sci. USA*
75:4194-4198 (1978).

Background of the Invention

Liposomes, or lipid bilayer vesicles, have been used or proposed for use in a
variety of diagnostic and therapeutic applications. Particularly in their use as carriers
in vivo of diagnostic or therapeutic compounds, the liposomes are typically prepared
to contain the compound in liposome-entrapped form.

Ideally, such liposomes can be prepared to include the entrapped compound (i) with high loading efficiency, (ii) at a high concentration of entrapped compound, and (iii) in a stable form, i.e., with little compound leakage on storage.

5 Methods for forming liposomes under conditions in which the compound to be entrapped is passively loaded into the liposomes are well known. Typically, a dried lipid film is hydrated with an aqueous phase medium, to form multi-lamellar vesicles which passively entrap compound during liposome formation. The compound may be either a lipophilic compound included in the dried lipid film, or a
10 water-soluble compound contained in the hydrating medium. For water-soluble compounds, this method gives rather poor encapsulation efficiencies, in which typically only 5-20% of the total compound in the final liposome suspension is in encapsulated form. Additional compound may be lost if the vesicles are further processed, i.e., by extrusion, to produce smaller, more uniformly sized liposomes.
15 The poor encapsulation efficiency limits the amount of compound that can be loaded into the liposomes, and can present costly compound-recovery costs in manufacturing.

20 A variety of other passive entrapment methods for forming compound-loaded liposomes, including solvent injection methods and a reverse-evaporation phase approach (Szoka and Papahadjopoulos, 1978) have been proposed. These methods tend to suffer from relatively poor loading efficiencies and/or difficult solvent handling problems.

25 It has also been proposed to passively load compounds into liposomes by incubating the compound with preformed liposomes at an elevated temperature at which the compound is relatively soluble, allowing the compound to equilibrate into the liposomes at this temperature, then lowering the temperature of the liposomes to precipitate compound within the liposomes. This method is limited by the relatively
30 poor encapsulation efficiencies which are characteristic of passive loading methods.

Also, the compound may be quickly lost from the liposomes at elevated temperature, e.g., body temperature.

Compound loading against an inside-to-outside pH or electrochemical liposome gradient has proven useful for loading ionizable compounds into liposomes. In theory, very high loading efficiencies can be achieved by employing suitable gradients, e.g., pH gradients of 2-4 units, and by proper selection of initial loading conditions (Nichols and Deamer, 1976). With this method, compound leakage from the liposomes will follow the loss of ion gradient from the liposomes. Therefore, compound can be stably retained in liposome-encapsulated form only as long as the ion gradient is maintained.

This gradient stability problem was addressed, and at least partially solved, by employing an ammonium salt gradient for compound loading (Haran, *et al.*, 1993). Here excess ammonium ions, which act as a source of protons in the liposomes, function in addition as a battery to replenish protons lost during storage, thus increasing the lifetime of the proton gradient, and therefore reducing the rate of leakage from the liposomes. The method is limited to ionizable amine compounds.

Lastly, the utility of precipitation for liposome loading was hypothesized in the literature. Lasic D.D. (1993).

Summary of the Invention

The invention includes a liposome composition comprising a suspension of liposomes contained in an aqueous bulk-phase medium; the liposomes comprising a
5 coprecipitate of an ionizable compound and a charged precipitating agent, where the concentrations of both the compound and the precipitating agent within the liposomes are severalfold higher than the compound and precipitating agent concentrations in the bulk-phase medium, respectively, and the concentration of
10 compound within the liposomes is not reduced by the presence in the suspension of a proton or alkali metal-ion ionophore. A composition as above, wherein the bulk phase medium is substantially free of the precipitating agent is preferred.

In one aspect of the above, the invention includes, a suspension of liposomes contained in an aqueous bulk-phase medium, and an ionizable compound
15 contained within the liposomes in the form of a coprecipitate with a charged, polyionic polymer which serves as the precipitating agent. The concentrations of both the compound and the polymer within the liposomes are severalfold higher than the compound and the polymer concentrations in the bulk-phase medium, respectively, and the concentration of compound within the liposomes is
20 substantially unaffected by the addition to the suspension of a proton or alkali metal-ion ionophore. The bulk phase medium may be substantially free of the precipitating agent.

In one general embodiment, the polymer is a polysulfate, polysulfonate,
25 polyphosphate, or polycarboxylate polymer, and, preferably, the compound is

ionizable by protonation to a positively charged form. An exemplary composition includes doxorubicin, or analog thereof, in combination with polyacrylate, chondroitin sulfate A, polyvinylsulfuric acid, or polyphosphoric acid.

5 In another general embodiment, the polymer is a polymeric base, and, preferably, the compound is ionizable by deprotonation to a negatively charged form.

10 In another aspect, the invention includes a liposome composition comprising a suspension of liposomes contained in an aqueous bulk-phase medium, and an ionizable compound contained within the liposomes in the form of a pH-induced precipitate. The concentration of the compound within the liposomes is severalfold higher than that in the bulk-phase medium, and the concentration of compound within the liposomes is not reduced by the presence in the suspension of a proton or
15 alkali metal-ion ionophore.

 Also forming part of the invention is a method of producing a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form. The method comprises adding a compound to be encapsulated to
20 a suspension of liposomes in bulk-phase aqueous medium, the liposomes having substantially no outside to inside pH or electrochemical ion gradient and containing charged precipitating agent of higher inside/lower outside concentration, and the precipitating agent being oppositely charged to the compound; and incubating under conditions that allow active uptake of the compounds by the precipitating agent. In
25 this method, the absence is in reference to the ion having the same charge sign as the compound to be loaded.

 In one embodiment, is a method which includes adding the compound to a dispersion of liposomes contained in a bulk-phase aqueous medium, where the
30 liposomes have a higher-inside/lower-outside gradient of a charged, polyionic polymer which can serve as the counterion of the compound. The compound-

containing dispersion is then incubated under conditions that allow uptake of the compound by the liposomes to a compound concentration that is severalfold that of the compound concentration in the bulk-phase medium, as evidenced by the formation of a precipitate inside the liposomes.

5

The incubating step may be carried out at a temperature above the phase transition temperature of lipids forming the liposomes. The method may further include removing unprecipitated compound from the bulk phase of the suspension, after compound loading.

10

In one general embodiment, the polymer is a polysulfate, polysulfonate, polyphosphate, or polycarboxylate polymer, and the compound is ionizable by protonation to a positively charged form, as above. In an exemplary method, the compound is doxorubicin, or an analog thereof, and the polymer is polyacrylate, chondroitin sulfate A, polyvinylsulfuric acid, or polyphosphoric acid.

15

In still another aspect, the invention includes a method of producing a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form, where the compound is relatively water insoluble at a first pH, and relatively water soluble at a second pH. The method includes adding the compound to a dispersion of liposomes contained in a bulk-phase aqueous medium, where the dispersion has an inside-to-outside liposome pH gradient corresponding to said first and second pH, respectively. The compound and dispersion are incubated under conditions which allow uptake of the compound by the liposomes to a compound concentration that is severalfold that of the compound concentration in the bulk-phase medium, as evidenced by the formation of a precipitate inside the liposomes.

20

25

30

In one embodiment, the inside-to-outside pH gradient may be opposite to that required for loading the same compound in soluble form into liposomes. The

method may further include adjusting the pH of the bulk phase medium to that of the internal liposome pH following the incubating step.

5 In a final aspect, the invention includes a method of producing a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form. The method includes adding the compound to a dispersion of liposomes contained in a bulk-phase aqueous medium, where the liposomes have (i) a higher inside/lower outside gradient of a multivalent, charged precipitating agent, and (ii) substantially no inside-to-outside pH gradient. The compound and
10 dispersion are then incubated under conditions that allow uptake of the compound by the liposomes to a compound concentration that is severalfold that of the compound concentration in the bulk-phase medium, as evidenced by the formation of a precipitate inside the liposomes.

15 In one general embodiment, the compound, when ionized, has a net positive charge, and the precipitating agent is a multivalent acid. The multivalent acid may be a polymer or non-polymer, organic or inorganic. For instance only, the multivalent acid may be a polysulfate, polysulfonate, polyphosphate or polycarboxylate. In an exemplary method, the compound is doxorubicin, or an analog thereof, and the
20 precipitating agent is tartrate, citrate, sulfate, phosphate, diethylene thiamine pentacetate, or polyacrylate. is polyacrylate, chondroitin sulfate A, polyvinylsulfuric acid, or polyphosphoric acid. In other words, in this embodiment, the precipitating agent may be polymeric or non-polymeric. The polymeric compounds may be, for example, polyacrylate, chondroitin sulfate A, polyvinyl sulfuric acid, or
25 polyphosphoric acid.

In another general embodiment, the compound, when ionized, has a net negative charge, and the precipitating agent is a multivalent organic base. The multivalent organic base may be polymeric or non-polymeric. In an exemplary
30 method, the compound is penicillin, and the organic base is benzathine.

These and other objects and features of the invention will become more fully apparent from the following detailed description of the invention is read in conjunction with the accompanying drawing.

5

Brief Description of the Drawing

Fig. 1 is a plot showing doxorubicin concentration in liposomes as a function of liposome/drug incubation time for liposomes loaded in the absence of a membrane-active ion carrier (•) and in the presence of valinomycin (•), CCCP (▽) or nigericin (▽) .

10

Detailed Description of the Invention

I. Liposome Composition with Precipitated Compound

15

This section describes a novel liposome composition containing liposomes suspended in a bulk-phase aqueous medium, and an ionizable compound contained within the liposomes in the form of a stable precipitate, at a concentration of compound that is several times that of the compound in the bulk-phase medium.

A. Charged-Polymer Precipitating Agent

In one general aspect, the compound entrapped in precipitated form is ionizable to a charged form, and the precipitating agent is a charged polymer which serves as the counterion of the compound. That is, the compound in ionized form has a net positive or negative charge, and the polymer charged groups have the opposite charge.

As the term is used herein, "polymers" refers to molecules consisting of repetitive units of preferably similar chemical structure, with molecular weights, roughly defined, from 400 to 2,000,000, soluble in water, and containing in their structure ionizable groups, that is, chemical functional groups capable of electrolytic dissociation resulting in the formation of ionic charge. The following are examples of such suitable polymers for use in the invention.

1. Acidic and basic polysaccharides, both natural and natural-derived, including: polygalacturonates, hyaluronic acid, gum arabic, chondroitin sulfates A, B, and C, keratin sulfates, dermatan sulfates, heparin and its derivatives, pectin and its derivatives, alginic (poly-anhydromannuronic) acid, teichoic acids, chitosans; derivatives of cellulose, amylose, amylopectin, dextran, or other neutral polysaccharide obtained by introduction of carboxyalkyl, phosphate, sulphate, amino-, mono-, di-, trialkylamino, tetraalkylammonium functional groups, derivatives of the said polysaccharides with nitrogen heterocycles, and derivatives obtained by grafting other ionizable functions to polysaccharide backbone.

2. Acidic and basic polypeptides and proteins, synthetic or natural: polymers and copolymers containing glutamic acid, aspartic acid, lysine, arginine, ornithine, other non-protein amino acids with ionizable function in the side chain, proteins with extremely high or low isoelectric points, such as cytochrome C, histone, protamine, trypsin, and partially hydrolyzed collagens.

3. Nucleic acids, oligo- and polynucleotides, and their derivatives.

4. Polymeric carboxylic acids: polymers and copolymers containing units of acrylic acid, methacrylic acid, maleic acid, propargylic acid, styrenecarboxylic acid, or other alkenyl- or alkenylarylcarboxylic acid; polymers and copolymers containing ionizable carboxyls in side groups on a polyamide, polyether, polyester, or polycyclic backbone.

5. Polymers with phosphate groups in the polymer backbone, such as polyphosphates, or in side chains, such as polyvinylphosphate.

6. Polymers bearing sulfo groups, such as: polyvinylsulfate, polyvinylsulfonate, polystyrenesulfonate, sulfated rosin gum (naphthenate).

7. Polymeric amines and amino containing heterocycles, whether in side groups or in the polymer backbone, such as: polyvinylamines, polyallyl amines, polyvinylalkylamines and polyvinyltrialkylammonium salts, polyvinylpyridines, quaternized polyvinylpyridines, poly(alkylaminoalkyl)acrylates, poly(aminoalkyl)vinyl alcohols, and copolymers containing the units of the above polymers.

8. Polymers containing thiocarboxylic, dithiocarboxylic, thiosulfate, and thiophosphate functions in side chains or in the main polymer backbone.

Compounds which are suitable in this embodiment are ionizable compounds whose solubility depends upon the presence of unneutralized charged groups. They are exemplified by the following pharmaceutical substances: antihistamine ethylenediamine derivatives (brompheniramine, diphenhydramine); Anti-protozoal: quinolones (iodoquinol); amidines (pentamidine); antihelmintics (pyrantel); anti-schistosomal drugs (oxaminiquine); antifungal triazole derivatives (fliconazole, itraconazole, ketoconazole, miconazole); antimicrobial cephalosporins (cefazolin,

cefonicid, cefotaxime, ceftazimide, cefuoxime); antimicrobial beta-lactam derivatives (aztreopam, cefmetazole, cefoxitin); antimicrobials of erythromycine group (erythromycin, azithromycin, clarithromycin, oleandomycin); penicillins (benzylpenicillin, phenoxymethylpenicillin, cloxacillin, methicillin, nafcillin, oxacillin, carbenicillin); tetracyclines (precipitate in the presence of Mg^{2+} and Zn^{2+} ; 5 other antimicrobial antibiotics, novobiocin, spectinomycin, vancomycin; antimycobacterial drugs: aminosalicylic acid, capreomycin, ethambutol, isoniazid, pyrazinamide, rifabutin, rifampin, clofazime; antiviral adamantanes: amantadine, rimantadine; quinidine derivatives: chloroquine, hydroxychloroquine, promaquine, qionone; antimicrobial qionolones: ciprofloxacin, enoxacin, lomefloxacin, nalidixic acid, norfloxacin, ofloxacin; sulfonamides; urinary tract antimicrobials: methenamine, nitrofurantoin, trimetoprim; nitroimidazoles: metronidazole; antineoplastic drugs: bleomycin, nitrogen mustards (chlorambucil, melphalan), nitrous bases and nucleoside analogs (cytarabine, dacarbazine, fludarabine, fluorouracil, mercaptopurine, thioguanine, procarbazine); anthracyclines 15 (doxorubicin, daunorubicin), antifolates (methotrexate), vinca derivatives (vincristine, vinblastine, vinorelbine), steroid derivatives (tamoxifen), ionic taxane derivatives; cholinergic quaternary ammonium compounds (ambethinium, neostigmine, physostigmine); anti-Alzheimer aminoacridines (tacrine); anti-Parkinsonal drugs (benztropine, biperiden, procyclidine, trihexylhenidyl); anti-muscarinic agents (atropine, hyoscyamine, scopolamine, propantheline); adrenergic dopamines (albuterol, dobutamine, ephedrine, epinephrine, norepinephrine, isoproterenol, metaproterenol, salmetrol, terbutaline); ergotamine derivatives; myorelaxants or curane series; central action myorelaxants; baclophen, 25 cyclobenzepine, dentrolene; nicotine; beta-adrenoblockers (acebutil, amiodarone); benzodiazepines (ditiazem); antiarrhythmic drugs (diisopyramide, encaidine, local anesthetic series - procaine, procainamide, lidocaine, flecaimide), quinidine; ACE inhibitors: captopril, enalaprilat, fosinoprol, quinapril, ramipril; antilipidemics: fluvastatin, gemfibrosil, HMG-coA inhibitors (pravastatin); hypotensive drugs: 30 clonidine, guanabenz, prazosin, guanethidine, granadril, hydralazine; and non-coronary vasodilators: dipyridamole.

An exemplary composition which employs a charged polymeric precipitating agent is described in Example 1, and includes the compound doxorubicin coprecipitated with polyacrylic acid. Example 3 describes a composition having the same compound, but precipitated with chondroitin sulfate A. Example 4 describes a similar drug composition, but precipitated with a polyvinylsulfuric acid polymer or a polyphosphoric acid polymer.

The selection of other suitable, co-precipitating ionizable compound/charged precipitating agent pairs is discussed in Section II below. At this point, it is noted only that the pair must exist in oppositely charged forms at a selected pH, preferably between about pH 4.5 and 9, more preferably in the pH range 6-8.

The concentration of precipitating agent inside the liposomes is preferably such that the concentration of charged groups, e.g., carboxyl, sulfate, or amine groups, is greater than the concentration of co-precipitated compound. In a composition having a final drug concentration of 100 mM, for example, the internal compound concentration of the polymer charge groups will typically be at least this great.

According to another aspect of the invention, the charged precipitating agent is present at a high-internal/low-external concentration; that is, there is a concentration gradient of agent across the liposome membranes in the composition. If the precipitating agent is present in significant amounts in the bulk phase, the agent can serve as a sink for liposome-entrapped precipitated compound, thus drawing off the compound over time. Preferably, the liposomes are prepared, as described in Section II below, so that the composition is substantially free of precipitating agent in the bulk phase (outside aqueous phase).

One unexpected feature of the invention is that the compound concentration in the liposomes is not reduced in the presence in the suspension of a proton or

alkali metal-ion ionophore, that is, an ionophore that has the ability to selectively promote proton or alkali metal-ion transport across a lipid bilayer membrane, when the ionophore is added to preformed liposomes. One explanation to this phenomenon is that the ionophore has no significant effect on the transport of the charged precipitating agents across the liposome bilayer membrane. Another explanation is that, in contrast to pH- or ammonium-ion gradient loading methods (Haran, et al., 1993; Mayer et al., 1985, 1986), the loading of a compound does not require maintaining of a transmembrane pH-, ammonium ion-, or other electrochemical ion gradient, as shown by Examples 7-9 below. This feature is illustrated in Fig. 1, where liposomes having an entrapped polyionic polymer (potassium polyacrylate) were loaded with doxorubicin in the presence of an ionophore, carbonyl cyanide m-chlorophenol hydrazone (CCCP, (∇), valinomycin (\bullet) or nigericin (∇). (Example 6). CCCP is specific to hydrogen protons, valinomycin is specific to potassium and hydrogen protons, and nigericin is specific to sodium, potassium and hydrogen protons. As seen in the figure, loading of doxorubicin was substantially unaffected by the presence of such ionophores, when compared to loading in the absence of an ionophore (\bullet).

Precipitation of drug within the liposome can be achieved by incorporation of non-charged polymers, in addition to charged, polyionic polymers discussed above. For example, polyvinyl pyrrolidone can be used to form a stable precipitate with a drug, where the precipitate is stabilized by hydrogen or van der Waals interactions between the polymer and the drug. Polyvinyl pyrrolidone is capable of forming coprecipitates with, for example, the anticoagulant warfarin and the antiinflammatory oxybutazone.

B. pH-Precipitated Compound

In another general aspect, the composition contains, as the liposome-entrapped compound, an ionizable compound that is in the form of a pH-induced precipitate.

Similar to the composition described in subsection A, the concentration of the compound within the liposomes in the present composition is several times higher than that in the bulk-phase medium, and the concentration of compound within the liposomes is substantially unaffected by the addition to the suspension of a proton or alkali metal-ion ionophore. Unlike the first-described composition, the retention of precipitated drug is not dependent on the maintenance of a gradient of precipitating agent. In fact, it may be desired to adjust the bulk-phase suspension to the pH at or near the internal pH at which the compound is precipitated.

Compounds suitable for use in the invention are those which have relatively low water solubility at a first pH, preferably in the pH range 3-9, and relatively high water solubility at a second pH, also preferably in the same pH range. Typically, the water solubility of compound at the second pH will be at least 10 times, and preferably 25-100 times or more, the water solubility of the compound at the first pH. Examples of suitable compounds include the following pharmaceutical compounds (solubility data are from AHFS DRUG REGISTER, 1996):

Cefalosporines (cefixime, cephalixin); tetracycline (solubility in water at acidic pH, 100 mg/ml; at neutral pH, 0.4 mg/ml); rifampin; acyclovir, gancyclovir (solubility in water at alkaline pH, >100 mg/ml; at pH 7.4, 2.5 mg/ml); quinolones: ciprofloxacin, enoxacin, nalidixic acid, norfloxacin, ofloxacin; norfloxacin having the following pH-dependent solubilities at 37°C:

pH <5.5	>40 mg/ml
pH 6.5	2.8 mg/ml
pH 7.0	1.5 mg/ml
pH 8.0	1.9 mg/ml

and ofloxacin, having the following pH dependent solubilities at room temperature:

pH 2.5	60 mg/ml
pH 7	4 mg/ml
pH 9.8	303 mg/ml

antitumor nitrogen mustard derivatives: melphalane; antiestrogens: tamoxifen; nitrous base analogs: thioguanine, mercaptopurine; dihydropyridine cardiovascular drugs: nicardipine, amlodipine, nifedipine, amrinone, whose pH dependent solubility is:

5

pH 4.1	25 mg/ml
pH 6	0.9 mg/ml
pH 8	0.9 mg/ml

10

non-steroid antiinflammatory agents: ibuprofen (soluble at alkaline pH, poorly soluble at neutral pH); HIV protease inhibitors: indinavir, ritonavir, and saquinavir.

The internal pH of the liposomes in the composition is preferably at or near the minimum-solubility pH of the precipitated compound, or at a lower pH of 4 to 5.5 or an upper pH of 8.5 to 10. As indicated above, the bulk phase pH may be adjusted to the internal pH, eliminating any transmembrane pH in the composition, particularly if necessary to bring the bulk phase pH within the range pH 6-8 suitable for parenteral use.

20

The liposome compositions of the invention are useful in a variety of diagnostics and therapeutic applications well known to those skilled in the art.

III. Preparing Liposome Compositions

In another general aspect, the invention includes a method of producing a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form, at a concentration of compound that is several times that of the compound in the bulk-phase medium.

30

A. Compound Loading by Charged Polymer

This method is useful in producing the liposome composition described in Section IA above. In practicing the method, liposomes are prepared to include an encapsulated charged polymer, such as listed in Section IA above. The polymer

used in the method will be one capable of precipitating the selected compound to be entrapped, and the polymer concentration will preferably be greater, in terms of charge-group concentration, than the final desired concentration of precipitated drug. (As used herein, "compound concentration" refers to the total amount of drug, in
5 both solute and precipitate form, in a given volume. Thus, for a compound in liposome-encapsulated form, the concentration of compound in the liposomes is determined from the total amount of compound contained in the liposomes divided by the total internal volume of the liposomes in the suspension, as calculated for example, from the total lipid concentration of the suspension.

10

Thus, for example, if the desired final concentration of compound in the liposomes is 100 mM, a final polymer concentration providing at least 100 mM in polymer charge groups should be selected. To identify a suitable polymer, various polymers taken for example from the list above are made up to the desired
15 concentration, at a selected pH typically around 6-8, and the selected compound is added to a concentration corresponding to the desired liposome-entrapped concentration. If a strong precipitation is observed, after a suitable incubation time, the polymer is suitable for that compound in the present method.

20

Liposomes having a higher-inside/lower-outside gradient of a charged, polyionic polymer are formed by preparing an aqueous polymer solution, using a polyionic polymer, selected as described above and at a concentration determined as described above. It is preferred that the polymer solution have a viscosity suitable for lipid hydration, described below. The pH of the aqueous polymer solution is
25 preferably such that the polymer is in charged form, and preferably the solution has a pH of between about 3-9, more preferably between about 5-8.

The aqueous polymer solution is used for hydration of a dried lipid film, prepared from conventional vesicle-forming lipids, including synthetic vesicle-
30 forming lipids and naturally-occurring vesicle-forming lipids. Exemplary vesicle-forming lipids include the phospholipids, such as phosphatidylcholine,

phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol, and sphingomyelin, where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation. These lipids can be obtained commercially or prepared according to published methods. Other
5 suitable lipids include glycolipids and sterols such as cholesterol. The vesicle-forming lipid can be neutral or charged.

The fluidity or rigidity of the liposome can be controlled to a certain extent by the vesicle-forming lipid used in forming the liposomes. Liposomes fluidity or
10 rigidity affects the rate of release of the entrapped drug in the liposome, and, in some cases it may be preferred to form liposomes having a more fluid nature to enhance release of the precipitated drug from the liposome.

Liposomes having a more rigid lipid bilayer, or a liquid crystalline bilayer,
15 are achieved by incorporation of a relatively rigid lipid, *e.g.*, a lipid having a relatively high phase transition temperature, *e.g.*, up to 60°C. Rigid, *i.e.*, saturated, lipids contribute to greater membrane rigidity in the lipid bilayer. Other lipid components, such as cholesterol, are also known to contribute to membrane rigidity in lipid bilayer structures.

20

On the other hand, lipid fluidity is achieved by incorporation of a relatively fluid lipid, typically one having a lipid phase with a relatively low liquid to liquid-crystalline phase transition temperature, *e.g.*, at or below room temperature.

25 A dried lipid film is prepared by dissolving the selected lipids in a suitable solvent, typically a volatile organic solvent, and evaporating the solvent to leave a dried film. The lipid film is hydrated with the aqueous polymer solution to form liposomes.

30 Example 1 describes preparation liposomes composed of the lipids egg phosphatidycholine (PC), cholesterol (CHOL) and polyethylene glycol derivatized

distearolphosphatidyl ethanolamine (PEG-DSPE). The lipids, at a molar ratio of 10:5:1 PC:CHOL:PEG-DSPE were dissolved in chloroform and the solvent was evaporated to form a lipid film. The lipid film was hydrated with an aqueous solution of sodium polyacrylate, to form liposomes having a higher-inside/lower-
5 outside gradient of a charged, polyionic polymer.

Liposomes are then sized to the desired size range, typically between 0.03-1 micron, preferably between 0.03 to 0.5 microns. A standard sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate
10 membranes having a selected uniform pore size in the range of 0.03 to 0.2 micron, typically 0.05, 0.08, 0.1, or 0.2 microns. The pore size of the membrane corresponds roughly to the largest sizes of liposomes produced by extrusion through that membrane, particularly where the preparation is extruded two or more times through the same membrane. Homogenization methods are also useful for down-
15 sizing liposomes to sizes of 100 nm or less.

After sizing, unencapsulated bulk phase polymer is removed by a suitable technique, such as dialysis, centrifugation, size exclusion chromatography or ion exchange to achieve a suspension of liposomes having a high concentration of
20 polymer inside and preferably little to no polymer outside.

The compound to be entrapped is then added to the liposome dispersion for active loading into the liposomes. The amount of compound added may be determined from the total amount of drug to be encapsulated, assuming 100%
25 encapsulation efficiency, i.e., where all of the added compound is eventually loaded into liposomes in the form of precipitate.

The mixture of the compound and liposome dispersion are incubated under conditions that allow uptake of the compound by the liposomes to a compound
30 concentration that is several times that of the compound in the bulk medium, as evidence by the formation of precipitate in the liposomes. The latter may be

confirmed, for example, by standard electron microscopy or x-ray diffraction techniques.

Typically, the incubating is carried out at an elevated temperature, and preferably above the phase transition temperature T_p of the liposome lipids. For high-phase transition lipids having a T_p of 50°C, for example, incubation may be carried out at between 55-60°C. The incubation time may vary from between an hour or less to up to 12 hours or more, depending on incubation temperature and the rate of permeation of the compound through the liposome membrane.

10

At the end of this incubation step, the suspension may be further treated to remove free (non-encapsulated) compound, e.g., using any of the methods mentioned above for removing free polymer from the initial liposome dispersion containing entrapped polymer.

15

B. Compound Loading by pH Precipitation

This method is useful in preparing the composition described in Section IB above, where the compound is relatively water insoluble at a first pH, and relatively water soluble at a second pH.

20

In practicing the method, the compound is added to a dispersion of liposomes having an inside-to-outside liposome pH gradient corresponding to the first and second pH, respectively. Specifically, the internal liposome pH is one at which the compound precipitates at low compound concentration, and the bulk phase pH is one at which the compound is relatively soluble. Exemplary compound solubilities for a variety of compounds suitable in the invention are given in Section IB above.

25

Liposomes are prepared to have an internal aqueous phase at a first pH where the compound to be loaded is relatively insoluble. Such liposomes can be

30

formed following the procedure described above in Section IIA, where a dried lipid film is hydrated with the aqueous phase at the desired, first pH.

5 After liposome formation, the external phase of the liposomes is adjusted, by titration, dialysis or the like, to a second pH where the compound to be loaded is relatively water soluble.

10 The compound to be entrapped is now added to the liposome dispersion, under conditions that allow uptake of the compound by the liposomes to a compound concentration that is several times that of the compound in the bulk medium, as evidenced by the formation of precipitate in the liposomes. Typical incubation temperatures and times follow those given in Section IIA above. At the end of this incubation step, the suspension may be further treated to remove free compound, also as above.

15 In addition, the pH of the bulk-phase suspension may be adjusted to a pH at or near the internal liposome pH. As noted above, this processing step is particularly useful if the internal pH is in the range from about 5.5 to 8.5, so that the final suspension has a physiological pH.

20

C. Compound Loading by Charged, Non-Polymeric Species

In accordance with the invention, a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form can also be prepared with multivalent, ionically charged organic compounds as
25 precipitating agents, whether polymeric or non-polymeric in nature.

In practicing the method, there is first prepared a dispersion of liposomes contained in a bulk-phase aqueous medium, and having (i) a higher inside/lower outside gradient of a multivalent, charged precipitating agent, and (ii) substantially
30 no inside-to-outside pH gradient.

Exemplary candidates for precipitating agents include phosphate, pyrophosphate, oligophosphates, fulfate, carbonate, tartrate, oxalate, citrate, nitrilotriacetate, ethylenediamine tetraacetate, diethylenetriamine pentaacetate, maleate, succinate, glutarate, 1,1,-bis(2-hydroxy 3-carboxynaphthyl)methane (pamoate)), as
5 negatively charged agents used in combination with a cationic ionizable compound. For a compound that is ionizable to a negatively charged species, the agent is a multivalent basic species, such as spermine, spermidine and their quaternized derivatives, N,N-bis(benzyl) ethylenediamine (benzathine), and procaine. It is appreciated that, in some instances, a precipitating agent within the invention may be
10 a non-valent acid, or base, that forms a precipitate with a compound to be loaded into the liposome, under the loading conditions (pH, temperature). One such precipitating agent, as an example, is Reinacke salt, especially when the compound is an organic amine.

15 To identify a suitable precipitating agent, for a selected ionizable compound, the compound is added to a solution of a test agent, similar to the approach used to identify suitable charged polymer agents described above in subsection IIA. Agents that show strong precipitation, at suitable compound and agent concentrations are suitable coprecipitating pairs for use in the invention. On the contrary, the agents
20 which are not precipitating agents for the compound cause very little compound loading (see examples 7-9).

One exemplary pair, for use in the invention, is doxorubicin or one of its derivatives, as a cationic ionizable compound, and an anion of phosphate, sulfate,
25 citrate, tartrate, diethylenetriamine pentaacetate, or polyacrylate. Another exemplary pair is penicillin or one of its derivatives, as a negatively charged compound, and benzathine, as a positively charged precipitating agent.

Liposomes having an inside/outside gradient of the precipitating agent are
30 prepared as in IIA above. The liposome dispersion is then incubated with the compound to be encapsulated, under conditions that allow uptake of the compound

into liposomes, also as described above. The final product may be further treated to remove free compound.

III. Examples

5 The following examples illustrate, but in no way are intended to limit, the present invention.

Example 1

Liposomes Loaded with Doxorubicin

21.6 mg of polyacrylic acid (molecular weight 2,000; Aldrich Corporation,
10 Milwaukee, WI) were dissolved in 3 ml of water and neutralized to pH 7.4 with NaOH to produce 100 milli-eq/L sodium polyacrylate solution. 10 mg of the mixture of egg PC, cholesterol, and PEG (molecular weight 2,000)-DSPE (Avanti Polar Lipids, Birmingham, AL) in the molar ratio of 10:5:1 was dissolved in chloroform, the solvent was evaporated in vacuum, the lipid film was incubated
15 with shaking in 1 ml of the above polyacrylate solution, and the lipid dispersion was extruded under pressure through 2 stacked Nucleopore (Pleasanton, CA) membranes with pore size 0.2 μ mol. The outer buffer was exchanged for NaCl 0.1 M containing 5 mM of sodium hydroxyethylpiperazine-ethane sulfonate (HEPES) at pH 7.4 using gel chromatography on Sepharose CL-4B (Pharmacia, Piscataway,
20 NJ); at the same time, untrapped sodium polyacrylate was also removed. To the so obtained liposomes, doxorubicin (Cetus Oncology, Norwalk, CT) was added at 200 nmol/ μ mol, of liposomal phospholipid. The mixture was incubated overnight at 37°C with shaking, treated with Dowex 50W x 4 (Sigma Chemical Co., St. Louis, MO), and equilibrated with NaCl-HEPES solution to remove non-
25 encapsulated doxorubicin. The resulting liposomes were sterilized by filtration through a 0.2 μ mol filter and assayed for doxorubicin by spectrophotometry and liposomal phospholipid by acid digestion-molybdene blue assay. Doxorubicin content was 129 nmol/ μ mol of liposomal phospholipid. Under similar conditions, doxorubicin loading into liposomes without entrapped sodium polyacrylate was 8
30 nmol/ μ mol of phospholipid.

Example 2**Cytotoxicity of Liposomal Doxorubicin**

Human nasopharyngeal epidermoid carcinoma (KB) cells were from American Type Culture Collection (ATCC, Rockville, MD). The cells were grown in RPMI 1640 medium supplemented with 10% heat inactivated fetal calf serum, harvested by trypsinization, and plated in 96-well tissue culture plates at 2×10^4 cells/well. After a 24 hour acclimation period, a solution of free doxorubicin or the doxorubicin liposomes described in Example 1 were added to the cells to achieve final doxorubicin concentrations of 0.125-8 $\mu\text{g/ml}$. "Empty" liposomes were added to control cells at matching concentrations of the lipid. After a 96 hour incubation period, viability of the cells was measured by tetrazolium assay (Carmichael, *et al.*, 1987). 50% growth inhibitory concentrations (IC_{50}) of the studied preparation were as follows:

Free doxorubicin	0.35 $\mu\text{g/ml}$
Liposomal doxorubicin	0.65 $\mu\text{g/ml}$
"Empty" liposomes	No growth inhibition detected

20

Example 3**Loading of Doxorubicin into Liposomes with Entrapped Sodium Salt of Chondroitin Sulfate A**

Liposomes were prepared as in Example 1, except that inner buffer, instead of polyacrylic acid, contained 5 mg/ml of chondroitinsulfate A (Sigma Chemical Co., St. Louis, MO). After overnight incubation with doxorubicin (100 mol/ μmol of phospholipid) at pH 7.2, free drug was removed from the liposomes, and the liposomes were assayed as in Example 1. The doxorubicin content in the resulting liposomes was 26.0 nmol/ μmol of phospholipid.

30

Example 4**Loading of Doxorubicin into Liposomes with Entrapped Sodium Salts of Sulfuric, Phosphoric, Polyvinylsulfuric, or Polyphosphoric Acid**

5 Liposomes were prepared from egg phosphatidylcholine using the procedure identical to Example 1 but instead of polyacrylic acid, the inner buffers contained one of the following salts: sodium sulfate, sodium phosphate, sodium polyvinylsulfate (Fluka, Ronkonkoma, NY; average chain length $n=13$), or sodium polyphosphate (Sigma Chemical Co.; average chain length $n=13-18$), at a
10 concentration of 100 milli-equivalents of sodium/L. The liposomes were incubated with doxorubicin (300 nmol/ μ mol of phospholipid) overnight, free drug was removed from the liposomes, and the liposomes were assayed as described in Example 1. Drug incorporation into the liposomes was as follows (in nmol/ μ mol of phospholipid): sodium sulfate, 82.1 ± 0.95 ; sodium phosphate, 76.8 ± 2.3 ;
15 sodium polyvinylsulfate, 109.8 ± 0.25 ; sodium polyphosphate, 85.2 ± 2.2 ; "blank" liposomes, containing 100 mM sodium chloride, 1.03 ± 0.06 .

Example 5**Loading of Doxorubicin into the Liposomes with Entrapped Sulfate, Phosphate, Polyvinylsulfate, or Polyphosphate Sodium Salts in the Presence of Nigericin**

 Liposomes were prepared and loading with doxorubicin as in Example 4, except that prior to drug loading, nigericin was added to the liposomes at a
25 concentration of 5 μ mol/L. The following drug incorporation (nmol/ μ mol of phospholipid) was obtained in the liposomes containing: sodium sulfate, 96.5 ± 1.9 ; sodium phosphate, 271.9 ± 3.8 ; sodium polyvinylsulfate, 133.7 ± 1.9 ; sodium polyphosphate, 169.7 ± 2.7 . Therefore, permeabilization of the liposome membrane to hydrogen and sodium ions by nigericin did not decrease drug loading.

30

Example 6**Effect of Membrane-Active Ion Carriers on the Loading of Doxorubicin into the Liposome with Entrapped Potassium Polyacrylate**

5 The liposomes prepared according to the present invention can be clearly distinguished from similar liposomes prepared by pH gradient, or ammonium ion gradient methods, by the liposomal response to membrane-active ion carriers which destroy transmembrane electrochemical gradients. For example, CCCP is a membrane proton carrier which destroys transmembrane pH gradients and leads to
10 quick release of a liposomal-entrapped compound. Nigericin, a membrane carrier for protons and monovalent ions, quickly releases doxorubicin from liposomes loaded by the ammonium ion method (Haran, *et al.*, 1993).

 In contrast, liposomes prepared according to this invention, load doxorubicin
15 in the presence of CCCP or nigericin with nearly the same efficiency as in the absence of such membrane-active ion carriers. This is shown in Fig. 1, where the loading of doxorubicin into liposomes in the presence of valinomycin, CCCP or nigericin was determined as a function of time. The liposomes were prepared as described in Example 1 to have entrapped potassium polyacrylate. The figure
20 shows that doxorubicin is loaded with substantially equal efficiency in the absence of a membrane-active carriers (•) and in the presence of valinomycin (•), CCCP (∇) or nigericin (∇).

Example 7**Loading of Doxorubicin into the Liposomes Containing Ammonium Salt of Polyacrylic or Sulfuric Acids in the Absence of Ammonium Ion Gradient.**

 Liposomes with entrapped ammonium sulfate or ammonium polyacrylate were prepared from the lipid mixture of hydrogenated soybean phosphatidylcholine (Avanti
30 PolarLipids, AL, USA), cholesterol (Calbiochem, USA), and poly(ethylene glycol) (Mol. weight 2,000) derivative of distearoyl phosphatidyl ethanolamine (PEG-DSPE)

(Sygena, Switzerland), at the molar ratio 60:40:6, by lipid film hydration, repetitive freezing-thawing at 60°C (6 times) and extrusion through two stacked polycarbonate track-etched membranes with the pore size 100 nm at 60°C (12 times). The bulk aqueous phase of the liposomes was exchanged by gel-filtration for the outer buffer, 0.2 M ammonium chloride, adjusted (when necessary) to pH 7.3 and buffered with 10 mM sodium hydroxyethylpiperazino-ethane sulfonate (HEPES). The inner (entrapped) solution had ammonium ion concentration of 200 milli-equivalent/L, i.e. the same as the outer buffer (no ammonium ion gradient), and the anion composition and pH as indicated below. Polyacrylic acid with mol. weight of 2,000 (Aldrich Chemical Co.) was used. Doxorubicin was added to the liposomes at 2 mg for each 6-8 micro-mol of phospholipid, and incubated with shaking at 60°C, i.e. above the transition temperature of the lipid bilayer, for various times as specified below. At this temperature, doxorubicin did not form a detectable precipitate in the presence of sulfate anion, but was visibly precipitated by a polyacrylate anion. Doxorubicin-loaded liposomes were separated from the free drug by gel-chromatography on Sephadex G-75, eluted with the outer buffer. Liposomal doxorubicin was assayed by spectrophotometry at 485 nm, phospholipid was quantitated by molybdate method after acid digestion of the liposomes. The following results were obtained:

Inner Buffer	Outer Buffer	Loading time	Doxorubicin incorporation into liposomes, mg of drug/mmol of liposome phospholipid
SO ₄ ²⁻ , pH 7.3	Cl ⁻ , pH 7.3	1 hour	6.1±0.8
SO ₄ ²⁻ , pH 7.3	Cl ⁻ , pH 7.3	16 hours	5.1±0.2
Polyacrylate, pH 5.2	Cl ⁻ , pH 5.2	1 hour	59.7±2.5
Polyacrylate, pH 7.3	Cl ⁻ , pH 7.3	1 hour	91.0±2.8

Thus, liposomes containing ammonium sulfate at 60°C in the absence of ammonium ion gradient absorbed very small amounts of doxorubicin, while the liposomes containing ammonium polyacrylate absorbed considerable amounts of doxorubicin even without ammonium ion gradient.

5

Example 8

Loading of Doxorubicin into Liposomes with Entrapped Anions and Essentially Free from Transmembrane pH or Ammonium Ion Gradients.

10 Aqueous solutions containing ammonium salts of hydrochloric, nitric, methanesulfonic, L(+)-tartaric, citric, sulfuric, phosphoric, diethylenetriamine pentaacetic (DTPA), or polyacrylic (Mol. weight. 2,000) acids were prepared by titration of the respective acids in water with the standard aqueous solution of ammonium hydroxide to achieve pH 7.3 ± 0.05 , followed by volume adjustment to
15 achieve 0.2 equivalent/L of ammonium ion, and, if necessary, by addition of dry sucrose to achieve osmolality of 377 mmol/kg. (These solutions are hereinafter referred to as Inner Buffers). All solutions additionally contained 10 mM
hydroxyethylpiperazinoethane sulfonic acid (HEPES) to stabilize the pH at titration endpoint. To afford determination of intraliposomal pH, a fluorescence indicator
20 8-hydroxypyrene trisulfonate was added to the solutions to the final concentration of 0.2 mM. Liposomes containing entrapped ammonium salt solutions as above were prepared from egg phosphatidyl choline, cholesterol, and PEG-DSPE as described in the Example 7, except that lipid hydration and extrusion were carried out at room temperature. The bulk aqueous phases of liposome preparations were exchanged by
25 gel-filtration for an aqueous solution (Outer buffer) containing 0.2 M ammonium chloride, 10 mM HEPES, pH 7.3, osmolality 377 mmol/kg, to obtain liposome preparations substantially without transmembrane ammonium-ion gradients. Loading of doxorubicin was performed as in Example 7, except that it was at 36°C for 12 hours. Intraliposomal pH was determined using HPTS fluorescence method
30 (Straubinger, *et al.*, 1990) prior to drug loading, and indicated essentially no inside-outside pH gradient (less than 0.2 pH units), compared with the gradient of

several pH units typical for ammonium ion gradient liposomes (Haran, *et al.*, 1993).

The following results were obtained (nd, not determined)

Inner Buffer anion composition	pH gradient, inside vs. outside.	Doxorubicin incorporation into liposomes, mg of drug/mmol of liposome phospholipid
chloride	-0.11	16.8
nitrate	-0.16	12.4
methanesulfonate	-0.21	17.1
L(+)-tartrate	nd	27.5
sulfate	nd	33.5
DTPA	nd	40.8
phosphate	nd	68.1
citrate	-0.13	97.9
polyacrylate	-0.02	142.7

5 Thus, "active loading" of doxorubicin was achieved in the liposomes containing organic or inorganic non-polymeric anions and essentially free from transmembrane pH- or ammonium ion gradients.

Example 9

10 Correlation between the Drug Precipitation by the Inner Buffer Anions and the Extent of Doxorubicin Loading into Liposomes with Entrapped Anions and Essentially Free from Transmembrane pH or Ammonium Ion Gradients.

15 Doxorubicin hydrochloride was added to the aliquots of Inner Buffers described in the Example 8 above to achieve final concentration of 1 mg/ml. The mixtures were briefly incubated at 60°C to effect maximum drug dissolution, and further equilibrated at ambient temperature (22°C) with gentle shaking for 3 hours. Precipitated doxorubicin was separated by centrifugation of an Eppendorf centrifuge (10,000 rpm, 5 min.), and the amount of doxorubicin in supernatant fluid was
20 determined by spectrophotometry. The percent of drug precipitation was calculated as

100% less the percent of doxorubicin remaining in the supernatant fluid relative to the total added doxorubicin.

The following results were obtained:

Inner Buffer anion composition	Doxorubicin precipitation, %
chloride	1.1
nitrate	0
methanesulfonate	0
L(+)-tartrate	25.0
sulfate	47.5
DTPA	58.1
phosphate	73.7
citrate	81.4
polyacrylate	98.4

5

It is apparent from the comparison with the data of Example 8 that doxorubicin loading in the absence of pH- or ammonium-ion gradient was effected when the liposome-entrapped anions, whether polymeric or non-polymeric, were capable of precipitating the drug. Using Student's *t*-test, statistically significant correlation was found between the extent of drug loading into the liposome and the drug solubility in the Inner Buffer (correlation coefficient $R=0.9043$; probability of null hypothesis $p<0.0005$).

10

IT IS CLAIMED:

1. A liposome composition comprising:

a suspension of liposomes contained in an aqueous bulk-phase medium; and

an ionizable compound contained within the liposomes in the form of a coprecipitate with a charged precipitating agent which serves as the counterion of the compound;

where the concentrations of both the ionizable compound and the charged precipitating agent within the liposomes are severalfold higher than the compound and precipitating agent concentrations in the bulk-phase medium, respectively, and the concentration of compound within the liposomes is not reduced by the presence in the suspension of a proton or alkali metal-ion ionophore.
2. A composition of claim 1, wherein the bulk phase medium is substantially free of said charged precipitating agent.
3. A composition of claim 1, wherein the precipitating agent is a polyionic polymer.
4. A composition of claim 3, wherein the compound is ionizable by protonation to a positively-charged form.
5. A composition of claim 4, wherein the polyionic polymer is a polymeric acid.
6. A composition of claim 3, wherein said compound is doxorubicin, or an analog thereof.

7. A composition of claim 6, wherein the polyionic polymer is selected from the group consisting of: polyacrylate; chondroitin sulfate A; polyvinylsulfuric acid and polyphosphoric acid.
8. A composition of claim 3, the compound is ionizable by deprotonation to a negatively-charged form.
9. A composition of claim 8, wherein the polyionic polymer is a polymeric base.
10. A composition of claim 1, wherein the charged precipitating agent is a polyionic non-polymer.
11. A composition of claim 10, wherein the polyionic non-polymer is the anion of a multivalent acid, and the ionizable compound is ionizable by protonation to a positively-charged form.
12. A composition of claim 11, wherein the ionizable compound is doxyrubicin, or an analogue thereof.
13. A composition of claim 12, wherein the polyionic non-polymer is selected from the group consisting of: phosphate; pyrophosphate; sulfate; citrate; tartrate; nitrilotriacetate; ethylenediamine tetraacetate and diethylenetriamine pentaacetate.
14. A composition of claim 10, wherein the polyionic non-polymer is the cation of a multivalent base, and the ionizable compound is ionizable by deprotonation to a negatively-charged form.
15. A composition of claim 14, wherein the ionizable compound is penicillin, or an analog thereof.
16. A composition of claim 15, wherein the multivalent base is benzathine.

17. A liposome composition comprising:

a suspension of liposomes contained in an aqueous bulk-phase medium; and

an ionizable compound contained within the liposomes in the form of a pH-induced precipitate;

where the concentration of the compound within the liposomes is severalfold higher than that in the bulk-phase medium, and the concentration of compound within the liposomes is not reduced in the presence in the suspension of a proton or alkali metal-ion ionophore.

18. A method of producing a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form, comprising:

adding an ionizable compound to a dispersion of liposomes contained in a bulk-phase aqueous medium, said liposomes having a higher inside/lower outside concentration of a charged, polyionic polymer which can serve as the counterion of the compound; and

incubating the compound-containing dispersion under conditions that allow uptake of the compound by the liposomes to a compound concentration that is severalfold that of the compound concentration in the bulk-phase medium, as evidenced by the formation of a precipitate inside the liposomes.

19. A method of claim 18, which further includes, after the incubating step, removing unencapsulated compound from the bulk phase of the suspension.

20. A method of claim 19, wherein the incubating step is carried out at a temperature above the phase transition temperature of lipids forming the liposomes.
21. A method of claim 18, wherein the ionizable compound is ionizable by protonation to a positively charged form.
22. A method of claim 21, wherein said charged, polyionic polymer is a polymeric acid.
23. A method of claim 18, wherein said compound is doxorubicin, or an analogue thereof.
24. A method of claim 23, wherein the charged, polyionic polymer is selected from the group consisting of: polyacrylate; chondroitin sulfate A; polyvinylsulfuric acid and polyphosphoric acid.
25. The method of claim 18, wherein the ionizable compound is ionizable by deprotonation to a negatively charged form and the polymer is a polymeric base.

26. A method of producing a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form, comprising:

adding an ionizable compound which is relatively water insoluble at a first pH and relatively water soluble at a second pH, to a dispersion of liposomes contained in a bulk-phase aqueous medium, said dispersion having an inside-to-outside liposome pH gradient corresponding to said first and second pH, respectively; and

incubating the compound-containing dispersion under conditions that allow uptake of the compound by the liposomes to a compound concentration that is severalfold that of the compound concentration in the bulk-phase medium, as evidenced by the formation of a precipitate inside the liposomes.

27. The method of claim 26, wherein the inside-to-outside pH gradient is opposite to that required for loading the drug in soluble form into liposomes.
28. The method of claim 26, which further includes adjusting the pH of the bulk phase medium to that of the internal liposome pH following the incubating step.
29. A method of producing a suspension of liposomes having an ionizable compound stably encapsulated in the liposomes in precipitated form, comprising:
- adding an ionizable compound to a suspension of liposomes contained in a bulk-phase aqueous medium, said liposomes having (i) a higher inside/lower outside concentration of a charged precipitating agent, and (ii) substantially no inside-to-outside pH gradient,

incubating the compound-containing dispersion under conditions that allow uptake of the compound by the liposomes to a compound concentration inside the liposomes that is severalfold that of the compound concentration in the bulk-phase medium, as evidenced by the formation of a precipitate inside the liposomes.

30. The method of claim 29, wherein the compound, when ionized, has a net positive charge, and the precipitating agent is a polymeric acid.
31. The method of claim 29, wherein said compound is doxorubicin, or an analog thereof, and the precipitating agent is selected from the group consisting of: polyacrylate; chondroitin sulfate A; polyvinylsulfuric acid and polyphosphoric acid.
32. The method of claim 29, wherein the compound, when ionized, has a net positive charge, and the precipitating agent is a multivalent, non-polymeric organic acid.
33. The method of claim 29, wherein the compound, when ionized, has a net negative charge, and the precipitating agent is a multivalent, non-polymeric organic base.
34. The method of claim 29, wherein the compound is penicillin, and the organic base is benzathine.




Fig. 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/18929

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 9/127 US CL :425/450; 264/4.1 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 425/450; 264/4.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) NONE														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X — A	HARAN et al., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et Biophysica Acta. 1993. vol 1151. pages 201-215, especially pages 201 and 205 through 210.	1-2, 10-17, 26-29 & 32-34 — 3-9, 18-25 & 30-31												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 05 JANUARY 1998		Date of mailing of the international search report 03 FEB 1998												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer G. S. KISHORE Telephone No. (703) 308-2350												

Form PCT/ISA/210 (second sheet)(July 1992)*

THIS PAGE BLANK (USPTO)